Keeping an eye on the ocular problems in dupilumab clinical trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment.Journal of clinical medicine · 2025
   Review
2. Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study.Journal of clinical medicine · 2022
   Article
3. Dupilumab-induced ocular surface disease: a primer.BMJ case reports · 2022
   Article
4. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae.Eye (London, England) · 2021
   Article
5. The association of chronic spontaneous urticaria (CSU) with anxiety and depression: a nationwide cohort study.Archives of dermatological research · 2021
   Article

Corrections and comments

• Comment on
  Conjunctivitis in dupilumab clinical trials.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as